Semaglutide

BACKGROUND: Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes an…

A patient in their early 20s with a complex psychiatric and medical history presented with severe electrolyte imbalance, dehydration, and progressive functional decline. After initial stabilisation, the patient developed recurrent episodes of hypoten…

Glucagon-like peptide-1 receptor (GLP1R) agonists, such as semaglutide, are used for treating type 2 diabetes mellitus and promoting weight loss. This study investigates genetic and molecular mechanisms underlying GLP1R activation using a novel in si…

OBJECTIVE: To evaluate the clinical efficacy and lipid metabolism impact of intensified treatment with degludec-aspart dual insulin combined with semaglutide in patients with type 2 diabetes. METHODS: A systematic comparison and analysis were conduct…

On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diab…

Cardiovascular diseases (CVDs) represent one of the leading causes of morbidity and mortality in patients with diabetes. However, a correct and effective glycaemic control obtained by pharmacologic interventions, such as the use the novel glucose-low…

The recent endorsement of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy), by the American College of Cardiology as first-line therapy for weight management marks a paradigm shift in cardiometabolic care. Semaglutide o…

: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underrep…

BACKGROUND: Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently been suggested as effective therapies to treat or reduce the risk of developing secondary lymphedema in patients with obesity; however, it is unknown whether the observed im…

Metabolic syndrome (MetS) represents the concurrent manifestation of multiple cardiometabolic risk factors, including visceral obesity, hyperglycemia, hypertension, hypertriglyceridemia, and low HDL-cholesterol, cumulatively predisposing to accelerat…

:and, two species traditionally used in Cameroon, are recognized for their weight-reducing potential. This study examined the effects of standardized extracts of these botanicals on glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase-4 (DPP-4), and…

BACKGROUND: Diabetic kidney disease (DKD) is a major microvascular complication of diabetes, often progressing silently and leading to end-stage kidney disease (ESKD) and cardiovascular morbidity. Early identification and risk-adapted intervention ar…

BACKGROUND: Coronary artery disease (CAD) imposes marked morbidity on patients, with many afflicted with debilitating residual symptoms despite optimal application of the available medical and surgical options. Glucagon-like peptide-1 (GLP-1) agonist…

BACKGROUND AND AIMS: Re-cellularization via electroporation therapy (ReCET) is an endoscopic procedure that uses electroporation to induce cellular apoptosis and subsequent re-epithelization in the duodenum. ReCET has demonstrated a positive effect o…

OBJECTIVE: The aim of this research is to evaluate the clinical and economic benefits of semaglutide in patients with type 2 diabetes mellitus (T2DM) in real-world setting in tertiary hospital in Saudi Arabia. METHODS: In this single-center retrospec…

Living donor liver transplant has recently become increasingly important as a solution to the shortage of deceased donor livers. The success of adult-to-adult living donor liver transplant depends on achievement of an appropriate graft-to-recipient w…